|View printer-friendly version|
|August 05, 2004 5:14 p.m.|
|Teva and Savient Receive Favorable Court Ruling on Human Growth Hormone Patent Suits|
Jerusalem, Israel, August 5, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today announced that the United States District Court for the District of Delaware has found invalid and unenforceable due to inequitable conduct, Novo Nordisks (NYSE:NVO) U.S. Patent No. 5,633,352 relating to recombinant human growth hormone. This ruling, which follows the completion of a trial in August 2003, paves the way for the U.S. commercialization of Savients FDA approved recombinant human growth hormone.